Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JX11502MA in Adults With Schizophrenia
CTR20213357Phase 2Completed
- Sponsor
- Jingxin Pharmaceutical
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing JX11502MA multiple-dose with Placebo (2 arms). Primary endpoints: Adverse events (AEs), Clinical laboratory tests and 4 more. Started Dec 2021; status: completed.
02
Drugs
JX11502MA
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20213357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213357.